Compare TROO & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TROO | AGEN |
|---|---|---|
| Founded | 2005 | 1994 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.5M | 126.8M |
| IPO Year | N/A | 2000 |
| Metric | TROO | AGEN |
|---|---|---|
| Price | $1.65 | $3.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 55.9K | ★ 456.3K |
| Earning Date | 12-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $15,084,000.00 | ★ $106,829,000.00 |
| Revenue This Year | N/A | $67.15 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 247.24 | N/A |
| 52 Week Low | $0.49 | $1.38 |
| 52 Week High | $2.62 | $7.34 |
| Indicator | TROO | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 70.41 | 38.61 |
| Support Level | $1.21 | $3.82 |
| Resistance Level | $1.75 | $4.12 |
| Average True Range (ATR) | 0.18 | 0.20 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 86.89 | 0.58 |
TROOPS Inc is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in money lending business in Hong Kong providing mortgage loans to high quality target borrowers, property investment to generate additional rental income and the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, large data and blockchain, and cloud computing (SaaS). It derives revenue from Hong Kong and Australia. Majority of its revenue generates from domestic market.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).